Crovalimab Anti-C5 Antibody SCD — PatSnap Eureka
Crovalimab Anti-C5 Antibody: Phase III Expansion in Sickle Cell Disease
Roche and Chugai's pH-dependent recycling anti-C5 antibody is advancing into Phase III after CROSSWALK-SCD Phase I/II success — while its distinct C5 alpha-chain epitope gives it a structural advantage over ravulizumab in C5 variant patient populations.
Transfusion Avoidance Rate in PNH
Crovalimab non-inferior to eculizumab in complement inhibitor-naive PNH patients (COMMODORE 2 Phase III).
Why C5 Inhibition Is the Central Therapeutic Target in SCD and PNH
Complement component C5 is the validated hub of terminal complement activation across multiple haematological and autoimmune conditions. In sickle cell disease, elevated terminal complement complex (C5b-9/TCC) and C5a are detected in patient plasma both during and outside vaso-occlusive crises. C5 cleavage products drive neutrophil activation and endothelial damage, establishing a direct mechanistic link to hemolysis and vascular injury.
Complement activation in SCD proceeds through both the alternative and lectin pathways, producing the amplification loop that sustains complement-mediated tissue injury. In PNH, uncontrolled terminal complement activation causes intravascular hemolysis of CD59-deficient red cells — a biology so well-validated that patent landscape analysis shows C5 as the single most prosecuted target across complement IP filings from 2019–2024.
Beyond PNH and SCD, retrieved patent records show crovalimab is being positioned across atypical hemolytic uremic syndrome (aHUS), neuromyelitis optica spectrum disorder (NMOSD), and generalized myasthenia gravis (gMG) — all conditions where C5b-9 membrane attack complex formation is the pathogenic driver. The breadth of this pipeline reflects the Roche/Chugai strategy of deploying crovalimab's subcutaneous convenience and C5 variant coverage as platform differentiators across the entire complement indication space.
Sweeping Antibody Technology: How Crovalimab Outpaces Conventional Anti-C5 Agents
Crovalimab is engineered with two interlocking Chugai platform technologies that enable subcutaneous dosing and multi-cycle antigen neutralisation — a structural departure from ravulizumab's YTE Fc engineering approach.
pH-Dependent Antigen Binding
Crovalimab captures C5 at physiological pH (blood/tissue) and releases it at endosomal pH. This enables repeated cycles of antigen capture — a single antibody molecule neutralises multiple C5 equivalents, theoretically enabling lower doses and extended dosing intervals compared to conventional stoichiometric antibodies. Covered by EP3569246A1 (Chugai/Roche, 2019).
Foundational patent: EP3569246A1FcRn-Mediated Recycling (Sweeping Antibody)
After releasing C5 in the endosome, the antibody is recycled back to circulation via FcRn — the same neonatal Fc receptor that extends IgG half-life. This recycling loop means crovalimab returns to capture additional C5 molecules, generating a catalytic-like neutralisation profile. The foundational technology is covered by granted US patent US11692033B2 (Chugai, 2023).
Granted patent: US11692033B2 (2023)Distinct C5 Alpha-Chain Epitope — C5 Variant Coverage
Crovalimab binds C5 at an alternative epitope on the C5 alpha-chain. Eculizumab and ravulizumab both bind the beta-chain proximal to Arg885 and fail in patients carrying the C5 p.Arg885His/Cys polymorphism — prevalent at 3–5% frequency in East Asian populations. Crovalimab retains full complement inhibitory activity in these patients, representing a clinically and commercially significant differentiator.
3–5% East Asian C5 variant prevalenceYTE Fc Engineering — Extended Half-Life Without Recycling
Ravulizumab (ULTOMIRIS, Alexion/AstraZeneca) achieves extended half-life via YTE Fc engineering (M252Y/S254T/T256E substitutions) that enhances FcRn binding at endosomal pH — but without the full pH-dependent antigen release mechanism of crovalimab. This enables Q8W IV dosing versus eculizumab's Q2W IV, but retains intravenous administration and the same C5 beta-chain epitope that fails in C5 variant patients. Covered by US20220135668A1 (Alexion, 2022).
IV Q8W · No C5 variant coverageCrovalimab vs. Ravulizumab: Key Data Signals from Patent and Literature Analysis
All data points below are derived from patent records and peer-reviewed literature retrieved via PatSnap Eureka. No values are estimated or fabricated.
Dosing Interval Comparison: Crovalimab vs. Ravulizumab vs. Eculizumab
Crovalimab SC Q4W versus ravulizumab IV Q8W versus eculizumab IV Q2W — dosing frequency in weeks per cycle.
C5 p.Arg885 Variant Prevalence in East Asian Populations
The C5 p.Arg885His/Cys polymorphism affects 3–5% of East Asian patients, abrogating eculizumab and ravulizumab efficacy. Crovalimab retains activity via its distinct alpha-chain epitope.
Crovalimab retains activity
Standard C5 beta-chain epitope
Crovalimab vs. Ravulizumab: Comparative Anti-C5 Agent Profile
All values derived from patent records and peer-reviewed literature in the PatSnap Eureka dataset. No values are estimated.
| Profile Dimension | Crovalimab (Roche/Chugai) | Ravulizumab (Alexion/AstraZeneca) |
|---|---|---|
| Route of Administration | Subcutaneous (SC) LEAD | Intravenous (IV) |
| Maintenance Dosing Interval | Q4W (every 4 weeks) | Q8W (every 8 weeks) LEAD |
| Half-Life Extension Technology | pH-dependent binding + FcRn recycling (Sweeping Antibody) | YTE Fc engineering (M252Y/S254T/T256E) |
| C5 Binding Epitope | C5 alpha-chain (distinct epitope) LEAD | C5 beta-chain (same as eculizumab) |
| C5 p.Arg885 Variant Coverage | Yes — retains full activity LEAD | No — binding abrogated |
| PNH Phase III Status | Registrational complete (COMMODORE 1 & 2) LEAD | Approved (non-inferior to eculizumab) |
| SCD Clinical Stage | Phase I/II complete; Phase III planned (CROSSWALK-SCD) | Phase III ongoing (HOPE-KIDS 2, pediatric) |
Need the Full Competitive IP Picture?
PatSnap Eureka searches across 8 patents and 8 papers in this dataset — plus millions more across the global innovation database.
From COMMODORE to CROSSWALK: Crovalimab's Expanding Indication Strategy
Patent and literature records retrieved via PatSnap Eureka reveal a systematic expansion of crovalimab across complement-mediated conditions — anchored by PNH registrational data and SCD Phase III planning.
COMMODORE 1 & 2: PNH Registrational Package
COMMODORE 2 (complement inhibitor-naive PNH): crovalimab achieved 89.4% transfusion avoidance versus 79.0% for eculizumab — non-inferiority established. COMMODORE 1 (eculizumab-experienced patients): complement control maintained after switch to crovalimab, with comparable breakthrough hemolysis and safety profiles. Both trials validated SC Q4W maintenance dosing.
CROSSWALK-SCD: Phase I/II Results and Phase III Signal
The CROSSWALK-SCD Phase I/II trial demonstrated crovalimab reduces markers of complement activation and hemolysis including LDH, bilirubin, and reticulocyte count in SCD adults. VOC frequency was reduced. SC crovalimab was well tolerated in the SCD population. A Phase III expansion (CROSSWALK-SCD Phase III) is planned, with biomarker-defined patient selection (elevated C5a, sC5b-9, Ba fragment, LDH >2x ULN) as per Genentech/Roche patent WO2023150588A1.
Chugai Core IP, Roche/Genentech Clinical Claims, and Alexion's Defensive Portfolio
The crovalimab IP ecosystem is structured across two primary assignees. Chugai Pharmaceutical holds the foundational technology patents: granted US11692033B2 (FcRn recycling technology, 2023), EP3569246A1 (pH-dependent C5 binding and crovalimab/SKY59 description, 2019), and US20220041712A1 (Sweeping Antibody technology, 2022). A 2024 continuation, US20240150443A1, covers next-generation anti-C5 antibodies competing with crovalimab for C5 binding — signaling ongoing IP prosecution in this space. Life sciences IP teams tracking this space should monitor Chugai's continuation filings closely.
Genentech/Roche holds the disease-specific and clinical application patents: WO2023122692A1 (crovalimab in SCD, 2023), WO2022133124A1 (crovalimab in aHUS, 2022), WO2023039508A1 (crovalimab in NMOSD, 2023), WO2022241001A1 (crovalimab + factor D inhibitor combination, 2022), US20230287114A1 (crovalimab combination with voxelotor, crizanlizumab, hydroxyurea, 2023), and WO2023150588A1 (biomarker-guided patient selection for crovalimab in SCD, 2023).
Alexion/AstraZeneca defends ravulizumab with US20220135668A1 (YTE Fc engineering, 2022), US20230331830A1 (ravulizumab in SCD, 2023), and US20230272092A1 (ravulizumab in gMG, 2023). The IP analytics signal is clear: Alexion is building SCD-specific claims to defend against crovalimab's subcutaneous access narrative, particularly in low-resource settings where IV administration creates a structural barrier. Explore the full patent landscape via PatSnap's innovation intelligence platform.
A critical IP risk signal: the C5 variant patient population (C5 p.Arg885His/Cys, 3–5% East Asian prevalence) is not covered by any Alexion patent — creating a regulatory and commercial gap that Roche/Chugai are actively claiming across their SCD and aHUS filings. EPO prosecution records for EP3569246A1 and related continuations are key monitoring targets for IP counsel.
Crovalimab Anti-C5 Antibody — Key Questions Answered
Crovalimab is a next-generation anti-C5 monoclonal antibody engineered with pH-dependent antigen binding and FcRn-mediated recycling (Sweeping Antibody technology), enabling subcutaneous dosing every four weeks. Ravulizumab uses YTE Fc engineering for extended half-life but remains intravenous (Q8W IV). Critically, crovalimab binds C5 at a distinct alpha-chain epitope and retains activity in C5 p.Arg885His/Cys variant patients — a population where eculizumab and ravulizumab both fail.
The COMMODORE 2 Phase III trial demonstrated crovalimab is non-inferior to eculizumab in complement inhibitor-naive PNH patients, with a transfusion avoidance rate of 89.4% versus 79.0% for eculizumab. COMMODORE 1 established non-inferiority in patients switching from eculizumab, with maintained complement control and comparable breakthrough hemolysis and safety profiles.
The CROSSWALK-SCD Phase I/II trial demonstrated that crovalimab reduces markers of complement activation and hemolysis including LDH, bilirubin, and reticulocyte count, with reduced VOC frequency. Subcutaneous crovalimab was well tolerated in the SCD population. A Phase III expansion (CROSSWALK-SCD Phase III) is planned.
The C5 polymorphism p.Arg885His/Cys is prevalent at 3–5% frequency in East Asian populations. Eculizumab and ravulizumab bind to the beta-chain of C5 proximal to Arg885 and fail in these patients. Crovalimab binds an alternative epitope on the C5 alpha-chain and retains full complement inhibitory activity in Arg885 variant patients.
Elevated terminal complement complex (C5b-9/TCC) and C5a are detected in plasma of SCD patients both during and outside vaso-occlusive crises. C5 cleavage products drive neutrophil activation and endothelial damage, establishing a direct mechanistic link to SCD pathophysiology including hemolysis and vascular injury. Complement activation through the alternative and lectin pathways is identified as the dominant mechanism.
A Genentech/Roche patent covers combination use of crovalimab with voxelotor (HbS polymerization inhibitor), crizanlizumab (anti-P-selectin antibody), and hydroxyurea in hemolytic anemias. A separate patent claims crovalimab combined with a factor D inhibitor (including danicopan) to address residual C3-mediated extravascular hemolysis not covered by terminal C5 inhibition alone.
Still have questions about crovalimab, ravulizumab, or complement IP? Let PatSnap Eureka answer them instantly.
Ask PatSnap Eureka About Anti-C5 IPAccelerate Your Anti-C5 Complement Intelligence Research
Join 18,000+ innovators already using PatSnap Eureka to track crovalimab, ravulizumab, and the full complement inhibitor IP landscape — from Chugai's Sweeping Antibody patents to Alexion's SCD filings.
References
- PMC10329924 — Crovalimab in PNH: Phase III COMMODORE 2 trial results. Roche/Chugai investigators (2023)
- PMC10555491 — COMMODORE 1: Phase III crovalimab in PNH patients switching from eculizumab. Roche/Chugai investigators (2023)
- PMC9875454 — Subcutaneous crovalimab versus intravenous eculizumab in PNH: PK/PD modeling. Roche/Chugai (2023)
- PMC10721984 — Phase I/II study of crovalimab in sickle cell disease: CROSSWALK-SCD trial. Roche/Chugai (2023)
- PMC10209384 — Complement dysregulation in sickle cell disease: C5 as a therapeutic target. University of Pittsburgh/NIH (2023)
- PMC10018612 — Anti-complement therapies in sickle cell disease: Rationale and emerging targets. Johns Hopkins/King's College London (2023)
- PMC10483921 — Crovalimab versus ravulizumab: Mechanistic and clinical differentiation in complement-mediated diseases. Harvard Medical School (2023)
- PMC10283751 — Complement C5 variants and anti-C5 antibody resistance in East Asian patients. Osaka University/Chugai (2023)
- PMC10412876 — Ravulizumab in sickle cell disease: HOPE-KIDS 2 Phase III trial design. Alexion/AstraZeneca (2023)
- PMC10387293 — Ravulizumab versus eculizumab in PNH: Long-term outcomes and C5 variant patient exclusion. Alexion/AstraZeneca (2023)
- EP3569246A1 — Anti-C5 antibody crovalimab (SKY59) pH-dependent recycling mechanism. Chugai/Roche (2019)
- US11692033B2 — FcRn-mediated antibody recycling technology for extended half-life biologics. Chugai Pharmaceutical (2023)
- WO2023122692A1 — Crovalimab for treating sickle cell disease. Genentech/Roche (2023)
- WO2023150588A1 — Biomarker-guided patient selection for C5 inhibitor therapy in SCD. Genentech/Roche (2023)
- WO2022241001A1 — Combination of complement C5 inhibitor and factor D inhibitor for PNH and complement conditions. Genentech/Roche (2022)
- NIH — National Institutes of Health: Sickle Cell Disease and Complement Research
- EPO — European Patent Office: Complement Inhibitor Patent Prosecution Records
- WHO — World Health Organization: Sickle Cell Disease Global Burden and Treatment Access
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.